TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections

Group 1 - Amicus Therapeutics Inc. (NASDAQ:FOLD) is identified as one of the 13 stocks with high upside potential, with a price target maintained at $14.50 by TD Cowen analyst Ritu Baral [1][2] - The company's fourth-quarter and full-year 2025 total product revenue slightly exceeded expectations, driven by strong performance of the Fabry disease medication Galafold, while Pompe disease medication revenues aligned with broader Wall Street expectations [1] - The strategic landscape for Amicus is shaped by BioMarin's agreement to acquire the company for $14.50 per share, with the deal expected to close by Q2 2026, pending shareholder and regulatory approvals [2] Group 2 - Amicus Therapeutics focuses on discovering, developing, and delivering medicines for individuals with metabolic diseases [3] - Despite the potential of Amicus as an investment, certain AI stocks are considered to offer greater upside potential with less downside risk [4]